Incretins, diabetes, pancreatitis and pancreatic cancer: What the GI specialist needs to know

Pancreatology

Volumn 16, Issue 1, 2016, Pages 10-13

  Forsmark, Chris E ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; METFORMIN; ANTIDIABETIC AGENT;

ACUTE PANCREATITIS; BODY MASS; CANCER RISK; CHRONIC PANCREATITIS; COLORECTAL CANCER; DIABETES MELLITUS; GALLSTONE; GLUCOSE INTOLERANCE; HEMORRHAGIC PANCREATITIS; HUMAN; MEDICAL SPECIALIST; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THYROID CANCER; DIABETES MELLITUS, TYPE 2; PANCREATIC NEOPLASMS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PANCREATIC NEOPLASMS; PANCREATITIS;

EID: 84956541198     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2015.11.009     Document Type: Review

References (42)

1. Anderson DK, Andren-Sandberg A, Duell EJ, Goggins M, Korc M, Petersen GH,et al. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCIworkshop. Pancreas 2013;42:1227-37.
2. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acutepancreatitis and biliary disease observed in patients with type 2 diabetes: aretrospective cohort study. Diabetes Care 2009;32:834-8.
3. Lai SW, Muo CH, Liao KE, Sung FC, Chen PC. Risk of acute pancreatitis in type 2diabetes and risk reduction on anti-diabetic drugs: a population-based cohortstudy in Taiwan. Am J Gastroenterol 2011;106:1697-704.
4. Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE,et al. Patients with type 2 diabetes mellitus have higher risk for acutepancreatitis compared to those without diabetes. Diabetes Obes Metab2010;12:766-71.
5. Shen HN, Chang YH, Chen HF, Lu CL, Li CY. Increased risk of severe acutepancreatitis in patients with diabetes. Diabet Med 2012;29:1419-24.
6. Yang L, He Z, Tang X, Liu J. Type 2 diabetes mellitus and the risk of acutepancreatitis. Eur J Gastro 2013;25:225-31.
7. Shen HN, Lu CL, Li CY. Effect of diabetes on severity and hospital mortality inpatients with acute pancreatitis: a national population-based study. DiabetesCare 2012;35:1061-6.
8. Malloy J, Gurney K, Shan K, Yan P, Chen S. Increased variability and abnormalitiesn pancreatic enzyme concentrations in otherwise asymptomaticsubjects with type 2 diabetes. Diabetes Metab Syndr Obes2012;5:419-24.
9. Steinberg W, Rosenstock J, De Vries JH, Thomsen AB. Elevated serum lipaseactivity in adults with Type 2 diabetes and no gastrointestinal symptoms.Gastroenterology 2012;142(Suppl 1):S93-4.
10. Steinberg William, Hans De Vries J, Wadden Thomas A, Jensen Christine Bjern,Svendsen Claus Bo, et al. Longitudinal monitoring of lipase and amylase inadults with type 2 diabetes and obesity: evidence from two phase 3 randomizedclinical trials with the once-daily GLP-1 analogue liraglutide.Gastroenterology 2012;142(Suppl 1):S850-1.
11. Das SL, Singh PP, Phillips AR, Murphy R, Windsor JA, Petrov MS. Newlydiagnosed diabetes mellitus after acute pancreatitis" a systematic review andmeta-analysis. Gut 2014;63:818-31.
12. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence ofdiabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes MetabRes Rev 2012;28:338-42.
13. Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, et al.Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis:recommendations from PancreasFest 2012. Pancreatology 2013;13:336-42.
14. Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP. Thedifferent courses of early- and late-onset idiopathic and alcoholic chronicpancreatitis. Gastroenterology 1994;107:1481-7.
15. Phillippe MF, Benabadji S, Barbot-Trystram L, Vadrot D, Boitard C, Larger E.Pancreatic volume and endocrine and exocrine function in patients withdiabetes. Pancreas 2011;40:359-63.
16. Hardt PD, Hauenschild A, Nalop J, Marzeion AM, Jaeger C, Teichmann J, et al.High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. Amulticenter study screening fecal elastase 1 concentrations in 1021 diabeticpatients. Pancreatology 2003;3:395-402.
17. Hahn JU, Kerner W, Maisonneuve P, Lowenfels AB, Lankisch PG. Low fecalelastase 1 levels do not indicate exocrine pancreatic insufficiency in type-1diabetes mellitus. Pancreas 2008;36:274-8.
18. Bilgin M, Balci NC, Momtahen AJ, Bilgin Y, Klor HU, Rau WS. MRI and MRCPfindings of the pancreas in patients with diabetes mellitus: compared withanalysis with pancreatic exocrine function determined by fecal elastase 1.J Clin Gastroenterol 2009;43:165-70.
19. Keller J, Layer P, Bruckel S, Jahr C, Rosien U. 13C-mixed triglyceride breath testfor evaluation of pancreatic exocrine function in diabetes mellitus. Pancreas2014;43:842-8.
20. Hardt PD, Ewald N. Exocrine pancreatic insufficiency in diabetes mellitus: acomplication of diabetic neuropathy or a different type of diabetes? ExpDiabetes Res 2011:761950 [epub].
21. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probabilityof pancreatic cancer following diabetes: a population-based study.Gastroenterology 2005;129:504-11.
22. Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, et al. Weightloss precedes cancer-specific symptoms in pancreatic cancer-associated diabetesmellitus. Pancreas 2011;40:768-72.
23. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR,Virtamo J, et al. Insulin, glucose, insulin resistance, and pancreatic cancer inmale smokers. JAMA 2005;294:2872-8.
24. Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, et al. Metformin is associated withreduced risk of pancreatic cancer in patients with Type 2 diabetes mellitus: asystematic review and meta-analysis. Diabetes Res Clin Pract 2014;106:19-26.
25. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabeticmedications and risk of pancreatic cancer in patients with diabetesmellitus: a systematic review and meta-analysis. Am J Gastroenterol2013;108:510-9.
26. Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J. Drug-inducedpancreatitis. Curr Gastroenterol Rep 2012;14:131-8.
27. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis,pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.Gastroenterology 2011;141:150-6.
28. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association ofpancreatitis with antidiabetic drug use: gaining insight through the FDApharmacovigilance database. Acta Diabetol 2013;50:569-77.
29. Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al.A cohort study of acute pancreatitis in relation to exenatide use. DiabetesObes Metab 2011;13:559-66.
30. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safetysurveillance system to assess the risk of acute pancreatitis with exanetide orsitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27.
31. Garg R, Chen W, Pendergrass M. Acute pancreatitis in Type 2 diabetes treatedwith exenatide or sitagliptin: a retrospective observational pharmacy claimsanalysis. Diabetes Care 2010;33:2349-54.
32. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerabilityof sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. DiabetesTher 2013;4:119-45.
33. Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretinbasedtherapies. Diabetologia 2014;57:1320-4.
34. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlikepeptide 1-based therapies and risk of hospitalization for acute pancreatitis intype 2 diabetes mellitus: a population-based matched case-control study.JAMA 2013;173:534-9.
35. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al.Pancreatic safety of incretin-based drugsdFDA and EMA assessment. N Engl JMed 2014;370:794-7.
36. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirschberg B, et al.Saxagliptin and cardiovascular outcomes in patients with type 2 diabetesmellitus. N Engl J Med 2013;369:1317-26.
37. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al.Alogliptin after acute coronary syndrome in patients with type 2 diabetes.N Engl J Med 2013;369:1327-35.
38. Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin baseddrugs and risk of acute pancreatitis: cohort study. BMJ 2014 Apr 24;348:g2780.
39. Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretintreatment and risk of pancreatitis in patients with type 2 diabetes mellitus:a systematic review and meta-analysis of randomised and non-randomisedstudies. BMJ 2014;348:g2366.
40. Raz I, Bhatt DL, Hirshberg B, Mosenzon O, Scirica BM, Umez-Eronini A, et al.Incidence of pancreatitis and pancreatic cancer in a randomized controlledtrial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.Diabetes Care 2014;37:2435-41.
41. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M,Butler PC. Marked expansion of exocrine and endocrine pancreas withincretin therapy in humans with increased exocrine pancreas dysplasia andthe potential for glucagon-producing neuroendocrine tumors. Diabetes2013;62:2595-604.
42. Halfdanarson TR, Pannala R. Incretics and the risk of neoplasis. BMJ 2013;346:f3750.